Evidence mapPaperPMID 30697254Full record

ArticleArchives of medical science : AMS2019

Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy.

Bernhard Jäger, Editha Piackova, Paul Michael Haller, Tijana Andric, Beatrice Kahl, Günther Christ, Alexander Geppert, Johann Wojta, Kurt Huber

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers.Archives of medical sciences. Atherosclerotic diseases · 2019
    Article
  16. Role of dyslipidemia in the development of early-onset preeclampsia.Journal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bernhard Jäger3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Editha Piackova3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Paul Michael Haller3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Tijana Andric3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Beatrice Kahl3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Günther Christ5 Medical Department with Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria.
Alexander Geppert3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Johann WojtaDepartment of Cardiology, Medical University Vienna, Vienna, Austria.
Kurt Huber3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Kaiser-Franz-Josef-Spital · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal duration of dual anti-platelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still a matter of debate. Biomarkers may help to identify patients who will benefit from extended DAPT. The aim of the study was to test the interaction between lipid parameters and platelet function in patients with coronary artery disease (CAD) on DAPT. MATERIAL AND

methodsOverall, 58 patients on DAPT were prospectively included following PCI in stable CAD. Platelet markers, i.e. mean platelet volume (MPV), platelet distribution width (PDW), fraction of reticulated thrombocytes (RT) and ADP-induced multiple electrode aggregometry (MEA), as well as serum lipids, i.e. high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG) and remnant cholesterol (RC), were assessed after intake of a maintenance dose of ASA and P2Y12 inhibitor.

resultsA significant inverse correlation was found for HDL-C levels and markers of platelet activation: MPV (

conclusionsWithin lipid parameters, only HDL-C levels are strongly associated with markers of platelet activation in CAD patients on DAPT. Accordingly, detection of dyslipidemia might indicate the need for prolongation of DAPT.

Indexed as

dyslipidemiahigh-density lipoprotein cholesterolP2Y12 inhibitorplatelet activationplatelet function

Identifiers

PMID30697254
PMCPMC6348363
OpenAlexW2913765432

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.